OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
PAR:OSE
Price:
3.29
EUR
7.8%
Market Closed
Market Cap:
€73.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
OSE Immunotherapeutics SA
PAR:OSE
|
FR |
|
Finbar Group Ltd
ASX:FRI
|
AU |
|
Samaraenergo PAO
MOEX:SAGO
|
RU |
|
Freelancer Ltd
ASX:FLN
|
AU |
|
Omeros Corp
NASDAQ:OMER
|
US |
|
Vladimirskiy Khimicheskiy Zavod PAO
MOEX:VLHZ
|
RU |
|
Fastenal Co
NASDAQ:FAST
|
US |
|
Puradelta Lestari Tbk PT
IDX:DMAS
|
ID |
|
D
|
Deutsche Telekom AG
XHAM:DTE
|
DE |
|
N
|
New Residential Urban Development Holdings Corp
VN:KDM
|
VN |
|
Tellgen Corp
SZSE:300642
|
CN |
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
US |
|
I
|
Innovative Designs Inc
OTC:IVDN
|
US |
|
Procurri Corporation Ltd
SGX:BVQ
|
SG |
|
Helport AI Ltd
NASDAQ:HPAI
|
SG |
Multiples-Based Value
The
Multiples-Based Value for
OSE Immunotherapeutics SA (OSE)
under the Base Case is
hidden
EUR.
Compared with the current market price of 3.29 EUR, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OSE Multiples-Based Value
LOCKED
Multiples Across Competitors
OSE Competitors Multiples
OSE Immunotherapeutics SA Competitors
OSE Immunotherapeutics SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
OSE Immunotherapeutics SA
PAR:OSE
|
73.8m EUR | 33.2 | -2.1 | -2 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
374.1B USD | 6.1 | 89.4 | 14.8 | 20.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.7B USD | 6 | 20.7 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 9.4 | 28.5 | 21.4 | 22.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41B EUR | 11.7 | 37.5 | 40.8 | 41.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3 | 33.4 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
